HeartSciences

#Cardiac Diagnostics #Electrocardiography #Artificial Intelligence in Cardiology

HeartSciences is a medical technology company advancing electrocardiography (ECG) through the integration of artificial intelligence. Its MyoVista Insights platform is a cloud-native, vendor- and device-agnostic ECG management system, while the MyoVista wavECG device delivers conventional resting 12-lead ECG functionality with on-device AI-enabled algorithms; the company has submitted the wavECG device to the FDA for 510(k) clearance. Incorporated in 2007 as Heart Test Laboratories and renamed HeartSciences in October 2024, the Southlake, Texas-based company listed on Nasdaq in June 2022. In June 2026 it announced a definitive all-stock business combination with Fortitude Mining Holdings, a vertically-integrated Zcash mining platform, under which existing HeartSciences holders would retain roughly 5% of the combined company.

Company Info

Sector:Medical Devices / AI-Enabled Electrocardiography

Headquarters:Southlake, Texas, USA

Founded:2007

Website:heartsciences.com/

Upcoming Milestones & Key Dates

H2 2026

Corporate Action

Expected closing of the all-stock business combination with Fortitude Mining Holdings, subject to HeartSciences shareholder approval

Clinical Development Pipeline

MyoVista wavECG Device

Target: Resting 12-lead ECG with AI-enabled on-device algorithms

Earlier detection of cardiac dysfunction, including impaired cardiac relaxation

Preclinical

Phase 1

Phase 2

Phase 3

Approved

MyoVista Insights Platform

Target: Device-agnostic, cloud-native ECG management with an AI-ECG algorithm marketplace

ECG data management and clinical decision support

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Andrew Simpson

Chief Executive Officer, President and Chairman of the Board

Danielle Watson

Chief Financial Officer and Treasurer

Careers & Job Openings

No active job listings. Check back later.